William Blair Investment Management LLC Sells 1,085 Shares of Vertex Pharmaceuticals Incorporated $VRTX

William Blair Investment Management LLC lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 3.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 31,087 shares of the pharmaceutical company’s stock after selling 1,085 shares during the quarter. William Blair Investment Management LLC’s holdings in Vertex Pharmaceuticals were worth $16,253,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Community Financial Services Group LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $26,000. Meeder Asset Management Inc. purchased a new position in Vertex Pharmaceuticals in the second quarter valued at about $26,000. MADDEN SECURITIES Corp purchased a new position in Vertex Pharmaceuticals in the third quarter valued at about $26,000. Elevation Wealth Partners LLC grew its stake in Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares in the last quarter. Finally, Pingora Partners LLC acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $32,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $538.60 on Monday. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $136.56 billion, a price-to-earnings ratio of 34.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a twelve month low of $412.27 and a twelve month high of $568.67. The business has a 50 day simple moving average of $522.37 and a 200-day simple moving average of $483.84.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the business earned $4.80 earnings per share. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on VRTX shares. Truist Financial lifted their price objective on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Cantor Fitzgerald increased their target price on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Barclays raised their price target on shares of Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Stifel Nicolaus lifted their price target on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the stock a “hold” rating in a research note on Tuesday, November 3rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $596.44.

View Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Featured Articles

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.